S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Biden's State of the Union to tout policy wins on economy
How will EU ban and West's price cap on Russian diesel work?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Evacuations urged in Ohio town as train wreck smolders
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
'Knock at the Cabin' knocks off 'Avatar' at the box office
Ally Financial expands NASCAR spend with 2 new partnerships
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Biden's State of the Union to tout policy wins on economy
How will EU ban and West's price cap on Russian diesel work?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Evacuations urged in Ohio town as train wreck smolders
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
'Knock at the Cabin' knocks off 'Avatar' at the box office
Ally Financial expands NASCAR spend with 2 new partnerships
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Biden's State of the Union to tout policy wins on economy
How will EU ban and West's price cap on Russian diesel work?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Evacuations urged in Ohio town as train wreck smolders
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
'Knock at the Cabin' knocks off 'Avatar' at the box office
Ally Financial expands NASCAR spend with 2 new partnerships
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Biden's State of the Union to tout policy wins on economy
How will EU ban and West's price cap on Russian diesel work?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Evacuations urged in Ohio town as train wreck smolders
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
'Knock at the Cabin' knocks off 'Avatar' at the box office
Ally Financial expands NASCAR spend with 2 new partnerships
NASDAQ:LPTX

Leap Therapeutics - LPTX Stock Forecast, Price & News

$0.63
-0.01 (-1.56%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.63
$0.66
50-Day Range
$0.42
$0.72
52-Week Range
$0.40
$2.57
Volume
349,840 shs
Average Volume
1.02 million shs
Market Capitalization
$62.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

Leap Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
376.2% Upside
$3.00 Price Target
Short Interest
Bearish
4.44% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.48) to ($0.41) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.86 out of 5 stars

Medical Sector

689th out of 1,025 stocks

Pharmaceutical Preparations Industry

338th out of 498 stocks

LPTX stock logo

About Leap Therapeutics (NASDAQ:LPTX) Stock

Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01, which is a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1 and TRX518, which is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.

Receive LPTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Leap Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LPTX Stock News Headlines

Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
LPTX Leap Therapeutics, Inc.
Leap Therapeutics: Q4 Earnings Insights
See More Headlines
Receive LPTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Leap Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LPTX Company Calendar

Last Earnings
11/14/2022
Today
2/05/2023
Next Earnings (Estimated)
3/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LPTX
Fax
N/A
Employees
36
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.00
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$2.50
Forecasted Upside/Downside
+376.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-40,590,000.00
Pretax Margin
-14,214.93%

Debt

Sales & Book Value

Annual Sales
$1.50 million
Book Value
$1.22 per share

Miscellaneous

Free Float
86,643,000
Market Cap
$62.38 million
Optionable
Not Optionable
Beta
0.72

Key Executives

  • Doug E. Onsi
    President, CEO, CFO, Secretary & Treasurer
  • Augustine J. Lawlor
    Chief Operating Officer
  • Cynthia Sirard
    Chief Medical Officer
  • Michael Haas
    Head-Research
  • Jason S. Baum
    Vice President & Head-Translational Medicine













LPTX Stock - Frequently Asked Questions

Should I buy or sell Leap Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Leap Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LPTX shares.
View LPTX analyst ratings
or view top-rated stocks.

What is Leap Therapeutics' stock price forecast for 2023?

3 brokerages have issued 12-month target prices for Leap Therapeutics' shares. Their LPTX share price forecasts range from $2.50 to $4.00. On average, they expect the company's stock price to reach $3.00 in the next year. This suggests a possible upside of 376.2% from the stock's current price.
View analysts price targets for LPTX
or view top-rated stocks among Wall Street analysts.

How have LPTX shares performed in 2023?

Leap Therapeutics' stock was trading at $0.45 at the beginning of the year. Since then, LPTX stock has increased by 40.0% and is now trading at $0.63.
View the best growth stocks for 2023 here
.

When is Leap Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 10th 2023.
View our LPTX earnings forecast
.

How were Leap Therapeutics' earnings last quarter?

Leap Therapeutics, Inc. (NASDAQ:LPTX) announced its quarterly earnings data on Monday, November, 14th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.02.

What other stocks do shareholders of Leap Therapeutics own?
What is Leap Therapeutics' stock symbol?

Leap Therapeutics trades on the NASDAQ under the ticker symbol "LPTX."

Who are Leap Therapeutics' major shareholders?

Leap Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Key Client Fiduciary Advisors LLC (1.36%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

How do I buy shares of Leap Therapeutics?

Shares of LPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Leap Therapeutics' stock price today?

One share of LPTX stock can currently be purchased for approximately $0.63.

How much money does Leap Therapeutics make?

Leap Therapeutics (NASDAQ:LPTX) has a market capitalization of $62.38 million and generates $1.50 million in revenue each year. The company earns $-40,590,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis.

How can I contact Leap Therapeutics?

Leap Therapeutics' mailing address is 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141. The official website for the company is www.leaptx.com. The company can be reached via phone at (617) 714-0360 or via email at heather@argotpartners.com.

This page (NASDAQ:LPTX) was last updated on 2/5/2023 by MarketBeat.com Staff